Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Esperion TherapeuticsESPR -0.31%62 Piotroski F-Score is 5 as of Aug. 04, 2026, which is 67% above its 10-year median of 3.00. GuruFocus rates ESPR with a GF Score™ of 62/100 and a GF Value™ of $2.30 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 979 Drug Manufacturers companies, Esperion Therapeutics ranks better than 60.06% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Esperion Therapeutics has an F-score of 5 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Esperion Therapeutics's Piotroski F-Score or its related term are showing as below:
ESPR'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 3 Max: 6
Current: 5
During the past 13 years, the highest Piotroski F-Score of Esperion Therapeutics was 6. The lowest was 2. And the median was 3.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Esperion Therapeutics Piotroski F-Score Related Terms
Esperion Therapeutics Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Esperion Therapeutics's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESPR vs AMPH, NIKA, BIOA: Piotroski F-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Esperion Therapeutics Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Esperion Therapeutics's current Net Income (TTM) was -7.4.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Esperion Therapeutics's current Cash Flow from Operations (TTM) was -18.2.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Esperion Therapeutics's return on assets of this year was -0.02290844. Esperion Therapeutics's return on assets of last year was -0.41071677.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Esperion Therapeutics's gearing of this year was 0.63896801. Esperion Therapeutics's gearing of last year was 0.7037016.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Esperion Therapeutics's current ratio of this year was 1.52970612. Esperion Therapeutics's current ratio of last year was 1.17645018.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Esperion Therapeutics's number of shares in issue this year was 251.353. Esperion Therapeutics's number of shares in issue last year was 196.128.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Esperion Therapeutics's gross margin of this year was 0.6837755. Esperion Therapeutics's gross margin of last year was 0.65303151.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Esperion Therapeutics's asset turnover of this year was 1.29076101. Esperion Therapeutics's asset turnover of last year was 0.69579692.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
0
+
1
+
1
+
0
+
1
+
1
=
5
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Esperion Therapeutics has an F-score of 5 indicating the company's financial situation is typical for a stable company.
Esperion Therapeutics (ESPR) has a Piotroski F-Score of 5 as of Aug. 04, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Esperion Therapeutics and its competitors. This is 67% above median its historical median of 3.00. Over the past decade, Esperion Therapeutics' Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, Esperion Therapeutics ranks #391 out of 979 companies in the Drug Manufacturers industry, placing it in the top 39.9%.
Is Esperion Therapeutics' Piotroski F-Score too high?
Esperion Therapeutics' current Piotroski F-Score of 5 is 67% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Esperion Therapeutics' value of 5 is 0% at this industry median. Based on the distribution chart, Esperion Therapeutics ranks #391 out of 979 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Esperion Therapeutics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Esperion Therapeutics' Piotroski F-Score compare to AMPH and NIKA?
According to the Drug Manufacturers industry distribution chart, Esperion Therapeutics ranks #391 out of 979 companies for Piotroski F-Score. This puts Esperion Therapeutics in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Esperion Therapeutics' value of 5 is 0% at this benchmark. Historically, Esperion Therapeutics' own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, Esperion Therapeutics has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Esperion Therapeutics's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Esperion Therapeutics and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Esperion Therapeutics's current Piotroski F-Score is 5, which is 67% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Esperion Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Esperion Therapeutics (ESPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.30, compared to a current price of $3.18 — trading 38.3% above its estimated fair value. The current Piotroski F-Score is 5, which is 67% above median its 10-year median of 3.00 and 0% at the Drug Manufacturers industry median of 5.00. Esperion Therapeutics' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Esperion Therapeutics (ESPR), the current Piotroski F-Score is 5 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Esperion Therapeutics (ESPR) Overvalued in 2026?
Based on GuruFocus' analysis, Esperion Therapeutics stock appears to be overvalued.
The current stock price of $3.18 is trading 38.3% above its estimated GF Value™ of $2.30.
GuruFocus considers Esperion Therapeutics to be Significantly Overvalued.
Key valuation signals for ESPR:
Piotroski F-Score: 5 (67% above median its 10-year median of 3.00)
GF Value™: $2.30 vs. price of $3.18 (38.3% above fair value)
Industry Position: 0% at the Drug Manufacturers median (#391 of 979)
No single metric tells the full story. See the ESPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
62GF Score
Get the complete analysis for ESPR
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESPR has been successfully added to your 
